image
Healthcare - Medical - Devices - NYSE - US
$ 55.43
-1.44 %
$ 1.71 B
Market Cap
13.04
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one CNMD stock under the worst case scenario is HIDDEN Compared to the current market price of 55.4 USD, CONMED Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one CNMD stock under the base case scenario is HIDDEN Compared to the current market price of 55.4 USD, CONMED Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one CNMD stock under the best case scenario is HIDDEN Compared to the current market price of 55.4 USD, CONMED Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CNMD

image
$80.0$80.0$75.0$75.0$70.0$70.0$65.0$65.0$60.0$60.0$55.0$55.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
1.31 B REVENUE
5.00%
200 M OPERATING INCOME
53.17%
132 M NET INCOME
105.44%
167 M OPERATING CASH FLOW
33.20%
-13.1 M INVESTING CASH FLOW
34.68%
-151 M FINANCING CASH FLOW
-36.74%
346 M REVENUE
9.23%
52.5 M OPERATING INCOME
-20.10%
33.8 M NET INCOME
-31.09%
43.3 M OPERATING CASH FLOW
-15.36%
-4.04 M INVESTING CASH FLOW
-18.16%
-51.1 M FINANCING CASH FLOW
-31.52%
Balance Sheet CONMED Corporation
image
Current Assets 640 M
Cash & Short-Term Investments 24.5 M
Receivables 238 M
Other Current Assets 378 M
Non-Current Assets 1.67 B
Long-Term Investments 0
PP&E 116 M
Other Non-Current Assets 1.55 B
10.31 %16.38 %5.02 %67.23 %Total Assets$2.3b
Current Liabilities 278 M
Accounts Payable 102 M
Short-Term Debt 715 K
Other Current Liabilities 175 M
Non-Current Liabilities 1.07 B
Long-Term Debt 905 M
Other Non-Current Liabilities 160 M
7.61 %13.04 %67.36 %11.94 %Total Liabilities$1.3b
EFFICIENCY
Earnings Waterfall CONMED Corporation
image
Revenue 1.31 B
Cost Of Revenue 574 M
Gross Profit 733 M
Operating Expenses 533 M
Operating Income 200 M
Other Expenses 67.9 M
Net Income 132 M
1b1b1b1b1b1b800m800m600m600m400m400m200m200m001b(574m)733m(533m)200m(68m)132mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
56.08% GROSS MARGIN
56.08%
15.33% OPERATING MARGIN
15.33%
10.13% NET MARGIN
10.13%
13.76% ROE
13.76%
5.74% ROA
5.74%
8.02% ROIC
8.02%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis CONMED Corporation
image
160m160m140m140m120m120m100m100m80m80m60m60m40m40m20m20m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 132 M
Depreciation & Amortization 16.6 M
Capital Expenditures -13.1 M
Stock-Based Compensation 25.6 M
Change in Working Capital 0
Others -19.8 M
Free Cash Flow 154 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets CONMED Corporation
image
Wall Street analysts predict an average 1-year price target for CNMD of $99.7 , with forecasts ranging from a low of $95 to a high of $107 .
CNMD Lowest Price Target Wall Street Target
95 USD 71.39%
CNMD Average Price Target Wall Street Target
99.7 USD 79.81%
CNMD Highest Price Target Wall Street Target
107 USD 93.04%
Price
Max Price Target
Min Price Target
Average Price Target
11011010010090908080707060605050May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.29% DIVIDEND YIELD
0.2 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.90.90.80.80.70.70.60.60.50.50.40.40.30.30.20.20.10.10.00.00.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.20.800.20.800.20.800.20.800.20.800.20.800.20.800.20.800.20.800.20.800.202015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership CONMED Corporation
image
Sold
0-3 MONTHS
16.8 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
287 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
544 K USD 4
9-12 MONTHS
7. News
CONMED Corporation to Announce First Quarter 2025 Financial Results on April 30, 2025 LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the first quarter 2025 after the market close on Wednesday, April 30, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed fro. businesswire.com - 2 weeks ago
CONMED Corporation Adds Mark Kaye to its Board of Directors LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Mark Kaye will be joining its Board of Directors effective February 24th, 2025. “My fellow directors and I are extremely pleased to welcome Mark to the board,” said Martha Goldberg Aronson, Chair of CONMED's Board of Directors. “Mark brings a wealth of experience to CONMED, including deep knowledge across finance, accounting, risk management, strategic planning, and operational efficiencies. He also brings a stro. businesswire.com - 1 month ago
CONMED Corporation Announces Quarterly Cash Dividend LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) announced today that its Board of Directors declared a quarterly cash dividend of $0.20 per share on February 24, 2025, payable on April 4, 2025, to all shareholders of record as of March 14, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, includ. businesswire.com - 1 month ago
New Strong Sell Stocks for February 19th ACDVF, BN and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on February 19, 2024. zacks.com - 1 month ago
New Strong Sell Stocks for February 11th ATS, CNMD and CSX have been added to the Zacks Rank #5 (Strong Sell) List on February 11, 2025. zacks.com - 2 months ago
CNMD's Q4 Earnings & Sales Beat Estimates, Stock Down on Weak Outlook CONMED reports solid fourth-quarter results, fueled by strength in the General Surgery segment and continued demand for AirSeal product. zacks.com - 2 months ago
Here's What Key Metrics Tell Us About Conmed (CNMD) Q4 Earnings Although the revenue and EPS for Conmed (CNMD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 2 months ago
CONMED Corporation (CNMD) Q4 2024 Earnings Call Transcript CONMED Corporation (NYSE:CNMD ) Q4 2024 Results Conference Call February 5, 2025 4:30 PM ET Company Participants Pat Beyer - Chief Executive Officer & President Todd Garner - Executive Vice President and Chief Financial Officer Conference Call Participants Rick Wise - Stifel Robbie Marcus - JPMorgan Vik Chopra - Wells Fargo Corporate & Investment Banking Young Li - Jefferies Travis Steed - BofA Securities Operator Thank you for standing by, and welcome to CONMED's Fourth Quarter Fiscal Year 2024 Earnings Conference Call. [Operator Instructions] Before the conference call begins, let me remind you that during this call, management will be making comments and statements regarding its financial outlook, its plans and objectives. seekingalpha.com - 2 months ago
Conmed (CNMD) Surpasses Q4 Earnings and Revenue Estimates Conmed (CNMD) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.20 per share. This compares to earnings of $1.06 per share a year ago. zacks.com - 2 months ago
CONMED Corporation Announces Fourth Quarter and Full-Year 2024 Financial Results LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2024. Fourth Quarter 2024 Highlights Sales of $345.9 million increased 5.8% year over year as reported and 6.0% in constant currency. Domestic revenue increased 6.8% year over year. International revenue increased 4.4% year over year as reported and 5.0% in constant currency. Diluted net earnings per share (GAAP) were $1.08 compared to diluted n. businesswire.com - 2 months ago
Conmed (CNMD) Earnings Expected to Grow: Should You Buy? Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 months ago
Should Value Investors Buy CONMED (CNMD) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 3 months ago
8. Profile Summary

CONMED Corporation CNMD

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 1.71 B
Dividend Yield 0.29%
Description CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Contact 11311 Concept Boulevard, Largo, FL, 33773-4908 https://www.conmed.com
IPO Date July 23, 1987
Employees 3900
Officers Ms. Hollie Foust Executive Vice President, General Counsel and Corporate Secretary Mr. Peter K. Shagory Executive Vice President of Strategy & Corporate Development Mr. Patrick J. Beyer President, Chief Executive Officer & Director Mr. Richard Glaze Chief Information Officer Mr. John Ferrell Executive Vice President of Human Resources Mr. Todd W. Garner CPA Executive Vice President, Chief Financial Officer & Principal Accounting Officer Ms. Shanna L. Cotti-Osmanski Executive Vice President of Information Technology & Chief Information Officer Mr. Curt R. Hartman Advisor Mr. David R. Murray President of ConMed Electrosurgery Ms. Johonna Marie Pelletier CPA Vice President of Tax & Treasurer